Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Axial Spondyloarthritis Clear all
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Withdrawn Early Phase 1 Interventional

Terbinafine Treatment of Axial Spondyloarthropathy

NCT05119712
View directory record Official record
Conditions
Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions
Terbinafine Tablets, Laboratory Testing
Drug · Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 27, 2023 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT02963506
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Anniston, Alabama • La Jolla, California • Upland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Not applicable Interventional

Clinical Investigation of MONTAGE in Adults With Spinal Deformity Undergoing Pedicle Subtraction Osteotomy

NCT04125147
View directory record Official record
Conditions
Fused Vertebrae, Ankylosing Spondylitis, Sagittal Deformities, Thoracolumbar Kyphosis
Interventions
Experimental: Montage Bone Hemostat
Device
Lead sponsor
Abyrx, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement

NCT01969188
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1 Interventional Results available

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

NCT02154425
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis
Interventions
Breast milk sampling, Certolizumab Pegol
Procedure · Biological
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Active, not recruiting Phase 4 Interventional

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

NCT04929210
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
38
States / cities
Avondale, Arizona • Chandler, Arizona • Mesa, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Study of Intra-articular Delivery of tgAAC94 in Inflammatory Arthritis Subjects

NCT00126724
View directory record Official record
Conditions
Arthritis, Rheumatoid, Arthritis, Psoriatic, Ankylosing Spondylitis
Interventions
tgAAC94 gene therapy vector, tgAAC94 placebo
Genetic
Lead sponsor
Targeted Genetics Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
22
States / cities
Glendale, Arizona • Tuscon, Arizona • Palm Desert, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2009 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis

NCT01087762
View directory record Official record
Conditions
Spondyloarthropathies
Interventions
CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
32
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)

NCT03502616
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Not applicable Interventional

The Impact of Simulated Forest Immersion Therapy on Pain and Anxiety in Patients Axial Spondyloarthritis (axSpA)

NCT06072859
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Humidified Forest Oils, Forest oils and audio-visual forest exposure
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis

NCT01109940
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457A
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study for Long Term Evaluation of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

NCT01118728
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Sarilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 20, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Not applicable Interventional

Prevention of Arthritis-Related Work Disability

NCT00000416
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis
Interventions
Rehabilitation counseling
Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 24, 2026, 5:34 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

NCT01209689
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

NCT00809159
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
AIN457, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
10
States / cities
Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting No phase listed Observational

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728
View directory record Official record
Conditions
Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy, Ankylosing Spondylitis, Post-traumatic Osteoarthritis, Rheumatoid Arthritis, Fracture, Infections
Interventions
Not listed
Lead sponsor
Exactech
Industry
Eligibility
21 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2031
U.S. locations
24
States / cities
Laguna Woods, California • Redwood City, California • Stockton, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Completed No phase listed Observational

Genetic Determinants of Ankylosing Spondylitis Severity - Longitudinal Study

NCT00056719
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Study of Golimumab in Participants With Active Ankylosing Spondylitis

NCT02186873
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, Golimumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Glendale, Arizona • Mesa, Arizona • La Palma, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

NCT00085644
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
adalimumab (D2E7), placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Sep 24, 2026, 5:34 AM EDT
Withdrawn Phase 3 Interventional

Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)

NCT01870284
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Ixekizumab, Placebo, Adalimumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 24, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis

NCT03129100
View directory record Official record
Conditions
Axial Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
23
States / cities
Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2022 · Synced Sep 24, 2026, 5:34 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 24, 2026, 5:34 AM EDT
Not yet recruiting Phase 4 Interventional

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

NCT07770646
View directory record Official record
Conditions
Axial Spondyloarthritis (AxSpA)
Interventions
Secukinumab (IL-17i ), Upadacitinib (JAKi)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 24, 2026, 5:34 AM EDT